CoChat

Development of Cagrilintide, a Long-Acting Amylin Analogue

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.1c00565

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 2

  1. Srinivasan A., 2020, J. Musculoskelet. Neuronal Interact., 20, 600
  2. World Health Organization. International nonproprietary names for pharmaceutical substances (INN), Drug Information, 2020; Vol. 34, pp 263–301. https://www.who.int/docs/default-source/international-nonproprietary-names-(inn)/pl123.pdf (accessed 9 Feb 2021).

Cited by

See all 129

Metadata

Authors
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk, Novo Nordisk Park, DK-2760 Maaloev, Denmark
Corresponding author
Kruse, Thomas
Venue
Journal of Medicinal Chemistry
Published
2021-07-21
Volume
64
Issue
15
Pages
11183-11194
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3187035249
Cited by
129
References
42
Citations by year
2026: 27 · 2025: 40 · 2024: 26 · 2023: 19 · 2022: 14 · 2021: 3
FWCI
9.05
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
cagrilintide, amylin analogues, long-acting insulin analogues, obesity, weight loss, semaglutide, GLP-1 receptor agonists, structure-activity relationship, clinical development
MeSH terms
Drug Development, Dose-Response Relationship, Drug, Humans, Hypoglycemic Agents, Models, Molecular, Structure-Activity Relationship, Molecular Structure, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of Cagrilintide, a Long-Acting Amylin Analogue. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c00565
The paper
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c00565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.